After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

Type 1 diabetes affects over 8 million people around the world. It’s a lifelong condition that occurs when the immune system ...

Vertex Pharmaceuticals Incorporated presented updated clinical data for zimislecel – VX-880) – its investigational stem ...

Vertex Pharmaceuticals got a fresh boost of confidence from H.C. Wainwright, which reaffirmed its Buy rating after the ADA ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C. Wainwright reaffirmed its Buy rating on ...

Zimislecel, a novel stem cell therapy, has reportedly demonstrated promising results in an early-phase clinical trial ...

Vertex Pharmaceuticals' stem cell therapy, Zimislecel, has shown potential to cure Type-1 diabetes, achieving insulin independence in 83% of patients during clinical trials.

More than 8 million people globally suffer from type 1 diabetes, a condition where the immune system destroys ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Diabetes affects many people in the world, type 1 diabetes being a condition that can affect anyone, causing them to be on ...

Discover how zimislecel enables insulin independence in patients with Type 1 diabetes, showing strong efficacy in early ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...